Standout of the week
Slate Medicines
Raleigh biotech developing biologic therapies for migraine prevention, launched February 2026 with a $130M Series A.
Pursuing a Nasdaq listing through a reverse merger with Fulcrum Therapeutics, with a $245M private placement led by Frazier Life Sciences.
Six months after emerging with $130M, Slate is merging with Massachusetts-based Fulcrum Therapeutics (Nasdaq: FULC) and expects to trade as SLTE after a fourth-quarter close. Securities filings cited by TBJ value Slate at $350M against $31.3M for Fulcrum; pre-merger Slate holders would own 55.9% of the combined company, private-placement investors 39.1%, and Fulcrum holders 5%, with Fulcrum paying an estimated $270M dividend and contributing roughly $20.3M in net cash. Proceeds fund operations into 2029, including Phase 1 and 2 studies of SLTE-1009, the anti-PACAP monoclonal antibody licensed from DartsBio that recently cleared a Phase 1 start in Australia with initial data expected mid-2027. The combined company keeps Slate's name, management, and board.
Deep dives
Capital
1 round
One transaction, and it is not a venture round. The $245M attached to the Fulcrum merger is a private placement, counted here separately from the disclosed-round totals in earlier editions so the two are not read as the same kind of money.
Infrastructure
A product launch that turns agentic-commerce readiness into a quarterly public index.
Institutions
Forge Nano breaks ground on its Morrisville battery-factory expansion
The August 19 company release confirms the groundbreaking. It targets nearly 315,000 square feet, roughly 3 GWh of annual capacity and more than 250 jobs, with production expected in 2028. These are planned capacity and jobs, not operating output or completed hiring.
UNC Health rebrands its venture arm and expands available investment capital
Chapelboro reports that Rex Health Ventures becomes UNC Health Ventures. A UNC Health spokesperson told the outlet the platform has $125 million for investments from reallocated capital reserves. This is investment capacity at a fund, not capital already received by Triangle startups, and is excluded from the edition’s company-financing total.
Coming up
Triangle
NC IDEA Fall 2026 MICRO and SEED applications close
MICRO ($10K) and SEED ($50K) non-dilutive grants.
Triangle
NC IDEA Foundations program applications close
The day after the MICRO and SEED deadline.
Durham
GrepBeat announces its 2026 Startups to Watch class
Sixth annual class of 10 early-stage NC tech startups.